Sixfold Bioscience is a preclinical-stage biotechnology company based in London. Sixfold develops next-generation in vivo delivery systems for Cell & Gene therapeutics. By integrating AI technology into Cell and Gene therapy development, Sixfold aims to expedite the R&D process, with the long-term aim of bringing true precision medicine to patients worldwide. While product approvals and regulatory focus made 2018 a breakthrough time for Cell and Gene therapies, the focus now shifts to finding safe and effective delivery systems to help unlock their true clinical and commercial potential. Sixfold is dedicated to providing a solution to the drug delivery challenge. We have very promising in vitro and in vivo data and are open to R&D collaboration opportunities to expand our pipeline.